Immune regulatory function of cancer-associated fibroblasts in non-small cell lung cancer

Hyewon Lee, Ph.D.¹*, Mina Hwang, Ph.D.²*, Seonae Jang, M.S.², Sang-Won Um, M.D., M.P.H., Ph.D.¹,²,#

¹Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul, Republic of Korea

²Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea

*Two authors contributed equally to this article.

Running Title: CAFs in lung cancer

Word count of the manuscript: 3902 /5000

Word count of the abstract: 250/250

#Corresponding author: Sang-Won Um, M.D., M.P.H., Ph.D.

Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, 06351, Republic of Korea and Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul, 06355, Republic of Korea. Tel.: +82-2-3410-1645;
Fax: +82-2-3410-3849; Email: sangwonum@skku.edu
Authors’ Contribution:

Conceptualization: Um SW
Methodology: Lee H, Hwang M, Um SW
Formal analysis: Lee H, Hwang M, Um SW
Data curation: Lee H, Hwang M, Jang S
Software: Lee H, Hwang M
Validation: Lee H, Hwang M, Um SW
Investigation: Lee H, Hwang M, Um SW
Writing - original draft preparation: Lee H, Um SW
Writing - revision: Hwang M, Um SW
Writing - review and editing: all authors
Approval of final manuscript: all authors.

Conflicts of interest

No potential conflict of interest relevant to this article was reported.

Funding

This study was supported by a 2018-grant from The Korean Academy of Tuberculosis and Respiratory Diseases and the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (2020R1A2C2006282).
Abstract

Background: Cancer-associated fibroblasts (CAFs) are key components of the tumor microenvironment and significantly contribute to immune evasion. We investigated the effects of CAFs on the immune function of CD4+ and CD8+ T cells in non-small cell lung cancer (NSCLC).

Methods: We isolated CAFs and normal fibroblasts (NFs) from tumors and normal lung tissues of NSCLC patients, respectively. CAFs were co-cultured with activated T cells to evaluate their immune regulatory function. We investigated the effect of CAF conditioned medium (CAF-CM) on the cytotoxicity of T cells. CAFs were also co-cultured with activated peripheral blood mononuclear cells and further incubated with cyclooxygenase-2 (COX2) inhibitors to investigate the potential role of COX2 in immune evasion.

Results: CAFs and NFs were isolated from the lung tissues (n = 8) and lymph nodes (n = 3) of NSCLC patients. Immune suppressive markers, such as COX2 and PD-L1, were increased in CAFs after coculture with activated T cells. Interestingly, CAFs promoted the expression of PD-1 in CD4+ and CD8+ T cells, and strongly inhibited T cell proliferation in allogenic and autologous pairs of CAFs and T cells. CAF-CM decreased the cytotoxicity of T cells. COX2 inhibitors partially restored the proliferation of CD4+ and CD8+ T cells, and downregulated the expression of COX2, prostaglandin E synthase, prostaglandin E2, and PD-L1 in CAFs.

Conclusions: CAFs promote immune evasion by suppressing the function of CD4+ and CD8+ T cells via their effects on COX2 and PD-L1 in NSCLC. The immunosuppressive function of CAFs could be alleviated by COX2 inhibitors.
**Keywords:** Primary lung cancer, cancer associated fibroblast, immune suppression, COX2, PD-L1
INTRODUCTION

Lung cancer is a leading cause of cancer-related mortality in the world and non-small cell lung cancer (NSCLC) accounts for approximately 85% of lung cancers. Tumor tissue consists of tumor cells, immune cells, and stromal cells such as fibroblasts and endothelial cells. As a result of high infiltration by immune and stromal cells, NSCLC has a relatively low level of tumor cell purity compared to other tumors. The interactions between tumor cells and tumor microenvironment (TME) trigger cancer metastasis and progression.

Cancer-associated fibroblasts (CAFs) are key components of the TME that influence matrix deposition and remodeling through their interactions with infiltrating immune cells and malignant cancer cells. CAFs secrete cytokines, chemokines, and growth factors, confer chemoresistance and promote cancer progression and metastasis. The prognostic significance of CAFs in breast and lung cancers has been reported previously.

Successful immunotherapy for cancers requires effective infiltration of CD8+ T cells inside the tumor, and tumors containing CAFs often have low levels of tumor-infiltrating lymphocytes (TILs). CAFs also promote immune suppression thorough their interactions with M2-like tumor-associated macrophages or myeloid-derived suppressor cells. Although CAFs regulate immunosuppression via their effects on tumor-infiltrating lymphocytes in TME, the interactions between T cells and CAFs in NSCLC remain unclear.

Cyclooxygenase (COX) has two isoforms: COX1 and COX2. COX1 maintains tissue homeostasis and is expressed in a variety of tissues. COX2-derived prostaglandin E2 (PGE2) facilitates the neointimal hyperplasia response to injury. COX2 is also
highly expressed in solid tumors such as colorectal, pancreatic, and lung cancers\textsuperscript{14-16}.

The pro-inflammatory enzyme COX2 and its downstream pathway product PGE2 promote immunosuppression, carcinogenesis, and tumor progression\textsuperscript{17,18}. COX2 expression is associated with PD-L1 expression in NSCLC and breast cancer\textsuperscript{19,20}. Therefore, COX2 inhibitors may be used as an adjuvant strategy for targeting cancers.

In the present study, we investigated the effects of CAFs on the immune function of CD4+ and CD8+ T cells, and evaluated the role of COX2 in immune evasion in NSCLC.

\section*{Material and Methods}

\subsection*{Patients and Samples}

Lung tumor tissues were obtained from patients who underwent surgery or endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) at Samsung Medical Center, Seoul, South Korea. Peripheral venous blood was collected from patients and healthy donors. The study protocol was approved by the Institutional Review Board of Samsung Medical Center (IRB no.: 2014-03-140) and all participants provided informed consent.

\subsection*{Cell Isolation and Culture of CAFs and NFs}

CAFs were isolated from tumor tissue, whereas normal fibroblasts (NFs) were isolated from the most distant non-tumor tissue from the resected lungs of NSCLC patients. The non-tumor and tumor specimens were washed three times with phosphate-buffered saline (PBS; Hyclone, Logan, UT, USA). Tissue specimens were minced into
1–2-mm$^3$-sized pieces and digested using 1 mL of 0.25% collagenase type I (Stemcell Technologies, Vancouver, Canada) at 37°C in an incubator for 30 minutes to 1 hour until single cells were >70%. After enzyme digestion, samples were centrifuged at 1300 rpm for 3 min. The pellets were resuspended in DMEM/F12 (Gibco, Invitrogen, Carlsbad, CA, USA), 10% fetal bovine serum (FBS; Gibco), and 1% antibiotic-antimycotic solution (Gibco). Next, the pellets were placed in 100-mm dishes. The cells were expanded for 7–14 days until they reached 90% confluence. The cells which migrated from seeded tissue fragments were collected after trypsin-EDTA (Gibco) treatment. The cells were passed through a 100 µm strainer (Falcon, Franklin Lakes, NJ, USA), and the collected cells were spread out on a 100-mm dish. Next, the cells were expanded to passage 3 and cryopreserved in complete DMEM with 10% dimethyl sulfoxide (Sigma-Aldrich, St. Louis, MO, USA) until analysis. CAFs were validated by negative expression of EpCAM or E-cadherin by flow cytometry or RT-PCR. Peripheral blood mononuclear cells (PBMCs) were isolated from buffy coats obtained from patients and healthy donors using Ficoll-Paque Plus (GE Healthcare Bio-science, Piscataway, NJ, USA).

**Co-cultures of CAFs/PBMCs and Proliferation Assays**

PBMCs were labeled with 1 µM carboxyfluorescein succinimidyl ester (CFSE; Invitrogen) in PBS and at 37°C for 15 min. Next, the cells were washed three times with PBS containing 5% inactivated FBS. After washing, the cells were plated in a 24-well plate ($1 \times 10^6$) at a 1:10 ratio (1 CAF per 10 PBMCs) in the absence or presence of CAFs. The cell culture medium included DMEM/F12 supplemented with 10% FBS and 1% antibiotic-antimycotic solution. PBMCs were stimulated or left unstimulated.
with an anti-human CD3 antibody (OKT3; 15 ng/mL; Biolegend, San Diego, CA, USA).

After 5 days, the PBMCs were harvested for flow cytometry. Most proliferation assays were performed using allogeneic PBMCs, whereas some experiments were performed using CAFs and PBMCs derived from the same patients (autologous pairs). Direct and indirect co-culture of CAFs and PBMCs was performed to evaluate the effect of direct cell-to-cell contact. To prevent contact between PBMCs and fibroblasts during indirect co-culture, a 24-well Transwell system (membrane with 0.4 μm pores; Falcon) was used; PBMCs were added to the upper chamber and fibroblasts were added to the lower chamber. After 5 days, PBMCs were analyzed by flow cytometry.

**Preparation of CAF Conditioned Medium (CAF-CM)**

CAFs were seeded on 100 mm dishes at $1 \times 10^6$ cells/mL with CAF culture medium (DMEM/F12 containing 10% FBS and 1% A/A). Two days after cell seeding, CAF culture medium was removed and 10 mL of serum-free CAF culture medium was added. After 2 days of incubation, the supernatant was collected and filtered with a 0.2 μm membrane (25AS020AS, Advantec) for sterilization. CAF-CM were stored at 4°C until use.

**Co-culture of PDOs/PBMCs and Tumor Organoid Killing Assay**

To investigate the influence of CAF-CM on the cytotoxicity of T cells, we performed a co-culture experiment using the autologous pair of patient-derived tumor organoids (PDOs) and PBMCs and a tumor organoid killing assay. Briefly, PDOs and PBMCs thawed in a 37°C water bath by gently swirling the vials. The cells were then immediately transferred to a large volume of pre-warmed media. After centrifugation, PDOs and PBMCs were mixed in a 1:2 ratio. Subsequently, the mixture of PDOs and
PBMCs were resuspended in 20 µl of 60% Cultrex reduced growth factor basement membrane extract type II (3533-010-02, Trevigen) and dispensed into ultralow-attachment 96-well plates (Corning) in triplicate. After solidifying the drops at 37°C for 15 minutes, the mixture of cells were co-cultured in organoid culture medium (advanced DMEM/F12 [Gibco], GlutaMax [Gibco], 100 ng/ml Noggin [Peprotech], 10% R-spondin-1 conditioned medium, 1x B27 supplement [Gibco], 1.25 mM N-acetylcysteine [Sigma-Aldrich], 10 mM nicotinamide [Sigma-Aldrich], 25 ng/mL human recombinant FGF-7 [Peprotech], 100 ng/mL human recombinant FGF-10 [Peprotech], 500 nM A83-01 [Tocris], 3µM CHIR99021 [4423, TOCRIS] and 5 mM Y-27632 [Enzo]) containing immune checkpoint inhibitors (ICPIs) or control antibody (pembrolizumab [A2002, Selleckchem], atezolizumab [A2004, Selleckchem], nivolumab [A2005, Selleckchem], or human IgG4 isotype control [403701, Biolegend]) in the presence or absence of 50% CAF-CM for 7 days. After 7 days of incubation period, the killing of tumor organoids by autologous T cells was assessed by CellTiter-Glo 3D Cell Viability Assay (G968B; Promega). The half of the culture media (100 µl) was removed from individual wells and 100 µl of CellTiter-Glo® 3D Reagent was added to it. After 30 minutes of incubation at room temperature on a shaker, supernatant in each well was transferred to a White Polystyrene 96-well Assay Plate (3912, Corning) and was analyzed with a Veritas Microplate Luminometer (Turner Biosystems). The organoid images were acquired with the Eclipse Ti2 microscope (NIKON Eclipse Ti2, Japan) using a ×20 objective lens before cell viability assay at day 7.

**Flow Cytometry**

Cells were washed and blocked with FACS buffer (1% bovine serum albumin
[BSA] in PBS). After blocking, the surface antigens of cells were labeled at 4°C for 20 min. Supplementary Table S1 lists the antibodies used in the study. To isolate single cells, the cell suspension was filtered through the FACS tube with cell strainer (35 µm) snap cap. The samples were acquired and analyzed using FACSVerse cytometer and FACSuite software (BD Biosciences, San Jose, CA, USA).

**Western Blot**

After cell culture, the cells were washed with cold PBS and treated with a lysis buffer (150 mM NaCl, 25 mM Tris–Cl, 1% NP-40, and 10 mM EDTA; pH 7.4) to lyse the cells. The protein concentration was quantified using BCA protein assay reagent (Pierce, Rockford, IL, USA). Next, 20 µg of protein per sample were subjected to SDS-PAGE. After electrophoresis, the proteins in the gel were transferred to a PVDF membrane (Bio-Rad, Richmond, CA, USA) for immunoblotting analysis. After the proteins were transferred, PVDF membranes were incubated for 1 h in 5% BSA in 1XTBST (150 mM NaCl, 50 mM Tris–Cl, and 0.1% Tween 20; pH 7.5), washed with 1XTBST, and incubated overnight at 4°C in the primary antibody diluted in 5% BSA in TBST. The PVDF membranes were washed and incubated with 5% BSA in TBST containing horseradish peroxidase-conjugated secondary antibody at room temperature for 1 h. The membranes were washed three times with TBST, treated with the Western blotting substrate (Pierce ECL; ThermoFisher Scientific, Waltham, MA, USA), and exposed to X-ray (Agpa, Mortsel, Belgium).

**WST Assay**
A cell viability assay kit (EZ-Cytox; DoGen, Seoul, Korea) was used to measure cell viability. CAFs were seeded in 96-well plates (1 × 10⁴ cells per well) and incubated at 37 °C and 5% CO₂ for 24 h. Next, the cells were incubated with different concentrations of the drug for 72 h, followed by treatment with EZ-Cytox for an additional hour and detection.

**Immunofluorescence**

Cells were fixed in 3.7% paraformaldehyde, permeabilized in 0.1% Triton X-100 in PBS for 10 min, and washed with PBS. Next, the cells were blocked with 1% BSA in PBS for 20 min, washed with PBS, and stained with primary antibodies overnight. The cells were washed and incubated with fluorescent dye-binding secondary antibodies. The nuclei were counterstained with 4′,6-diamidino-2-phenylindole (DAPI), and the images of cells were visualized using a laser scanning confocal microscope (Zeiss LSM780; Carl Zeiss Meditec, Jena, Germany).

**Real-time Polymerase Chain Reaction (PCR)**

Total RNA was extracted from fibroblasts using RNeasy Mini Kit (Qiagen, Hilden, Germany) in accordance with the manufacturer's guidelines, and quantified using spectrophotometry (Nanodrop 2000; ThermoFisher Scientific). Next, SuperScript® III First-Strand Synthesis System (ThermoFisher Scientific) was used to reverse transcribe the total RNA, and ABI 7900 HT Fast Real Time PCR system (Applied Biosystems, Foster City, CA, USA) was used to perform real-time PCR.
PCR was performed using SYBR Green PCR Master Mix (Applied Biosystems) under the following thermal cycling conditions: 95°C for 10 min, followed by 40 cycles at 95°C for 15 s, 52°C for 15 s, and 72°C for 30 s. To confirm the PCR quality, measurements were performed in triplicate and post-PCR melt curve was analyzed. The Ct value (i.e., the number of cycles in which the detected fluorescence exceeds the threshold) was determined. The comparative Ct method was used to normalize the mRNA level of the gene of interest to the reference gene lyceraldehyde-3 phosphate dehydrogenase (GAPDH); the mRNA level was expressed as fold difference. Supplementary Table S2 lists the primer sequences used in this study.

**PGE2 Enzyme-linked Immunosorbent Assay (ELISA)**

The PGE2 concentration was determined from a standard curve using a commercial ELISA kit (Cayman Chemical Company, Ann Arbor, MI, USA) following the manufacturer’s protocol. For PGE2 concentration measurement, samples were diluted 100-fold with assay buffer and expressed as ng/mL of protein.

**Statistical Analysis**

Statistical analyses were performed using GraphPad Prism software (GraphPad Software Inc., San Diego, CA, USA). Tukey’s multiple comparison test and one-way analysis of variance (ANOVA) were used for multiple comparisons. Two-tailed unpaired t-tests were used for simple comparisons. P < 0.05 was considered statistically
significant, and significant differences are marked with asterisks (*p < 0.05, **p < 0.01, ***p < 0.001, and ns = not significant).

RESULTS

Characterization of CAFs and NFs in NSCLC

We isolated CAFs and NFs derived from tumor and non-tumor tissues of NSCLC patients, respectively. Table 1 lists the clinical characteristics of CAFs and NFs. CAFs and NFs were isolated from the lung tissues (n = 8) and lymph nodes (n = 3).

During the early stage of the primary culture period, epithelial cells and fibroblasts grow together from the dissociated cells attached to the culture plate. However, after 1-2 passages, epithelial cells no longer grow, but only the fibroblasts grow in the culture plate (Figure 1A). Immunocytochemical analysis revealed that the presence of α-SMA, a candidate marker of CAFs, was confined to the cytoplasm of CAFs (Figure 1B). The mRNA expression of fibroblast-associated genes, including ACTA2 (α-SMA), FSP1 (S100A4), FAP, TNC, ITGA11, PDGN, PDGFRA, and PDGFRB, was analyzed in CAF and NF pairs from two patients (TH122 and TH131) using real-time PCR. CAFs exhibited high mRNA expressions of ACTA2, PDGFRB, PDGN, and ITGA11, and low mRNA expression of TNC (Figure 1C).

Gene Expression of Immunological Markers in Human Lung CAFs
We studied the mRNA expression of membrane HLA class II molecules to investigate whether CAFs are immune competent. HLA class I molecules are expressed on most somatic cells, whereas HLA class II molecules are usually expressed only on a subtype of immune cells, including activated T cells, B cells and antigen-presenting cells\textsuperscript{21}. To investigate the mRNA expression of immunological markers in CAFs after co-culture with activated T cells, CAFs were co-cultured with PBMCs from healthy donors with or without OKT3 for 5 days. PBMCs without OKT3 stimulation exhibited significantly increased mRNA expressions of \textit{CD40}, \textit{CD80}, and \textit{HLA-DR} in CAFs. Furthermore, co-culture of CAFs and activated PBMCs with OKT3 stimulation was associated with significantly increased mRNA expressions of \textit{PD-L1}, \textit{PD-L2}, and \textit{COX2} (Figure 2A). Therefore, the mRNA expression of immunological markers was increased in CAFs after co-culture with PBMCs.

PD-L1 and COX2 are Highly Expressed in CAFs after Co-culture with Activated T Cells

We investigated the expression of immunosuppressive molecules, such as COX2 and PD-L1, which are expressed in stromal fibroblasts\textsuperscript{22-24}. To explore the role of COX2 and PD-L1 in CAFs, we evaluated their gene expression in CAFs with or without activated PBMCs. The mRNA end-point PCR revealed that the gene expressions of COX2 and PD-L1 were significantly higher in PBMC-activated CAFs than CAFs alone (Figure 2B). The Western blot analysis revealed that the protein expressions of COX2 and PD-L1 were significantly higher in PBMC-activated CAFs than CAFs alone (Figure 2C). The intracytoplasmic and intranuclear localizations of COX2 and PD-L1 were confirmed by immunocytochemistry (Figure 2D).
To investigate how CAFs affect the proliferative response of T cells, CFSE-labeled PBMCs from healthy donors were cultured with or without patient-derived CAFs that were or were not stimulated by OKT3 for 5 days (Figure 3A). When only T cells were cultured, proliferation was increased by OKT3 stimulation. However, co-culture with allogenic CAFs significantly decreased the proliferation of CD4+ and CD8+ T cells (Figure 3A and B). We performed several experiments using autologous PBMCs to investigate whether MHC mismatch between CAFs and PBMCs affected the assay results. Similar effects were observed when PBMCs and CAFs from the same patient (autologous pairs) were co-cultured (Figure 3C and D). Furthermore, after OKT3 stimulation, the population of CD8+ T cells increased by 10.24% (from 24.27% to 34.51%) in the absence of CAFs and increased only by 1.84% (from 22.83% to 24.67%) in the presence of CAFs (Figure 3E). Similar results were observed for autologous pairs of PBMCs and CAFs (Figure 3F). These results suggest that CAFs inhibit CD4+ and CD8+ T cell proliferation and suppress the increase in CD8+ T cells among the stimulated CD3+ T cells.

**CAFs Promote the Expression of PD-1 in Cytotoxic T and Helper T Cells**

Immune checkpoints that are highly expressed in the TME suppress antitumor immunity, and are associated with cancer progression and a poor prognosis. We investigated whether CAFs are involved in the protein expression of immunosuppressive molecules, such as PD1, CTLA4, LAG3, and TIM3. Co-culture of allogenic CAFs significantly induced the protein expression of PD1 in CD4+ and CD8+ T cells (Figure 4A and B), but did not increase the protein expressions of CTLA4, LAG3,
and TIM3 (Figure 4C and D).

**Inhibition of T-cell Cytotoxicity by CAF-CM**

Next, to further elucidate the mechanism of immune evasion by CAF, we investigated the effect of CAF-CM on the cytotoxicity of T cells. We performed tumor organoid killing assay using the autologous pair of PDOs and PMBCs (TH189). CAF-CM was also harvested using CAFs derived from the same patient (TH189). The mixture of PDO and PBMC (1:2) were cultured for 7 days with ICPIs (pembrolizumab, nivolumab and atezolizumab) in the presence or absence of CAF-CM. After 7 days of co-culture, the killing of tumor organoids by autologous T cells were significantly reduced by the treatment of CAF-CM in pembrolizumab, nivolumab, and atezolizumab groups, respectively (all p < 0.05, Figure 5A). Representative light microscopy images also showed that the sizes of tumor organoids were smaller in the groups without CAF-CM than in those with CAF-CM (Figure 5B).

**COX2 Inhibitors Restored T Cell Proliferation and CD8+ T Cell Subset**

To investigate the roles of COX2 and PD-L1 in the immunosuppressive function of CAFs, we evaluated the effects of COX2 inhibitors, such as celecoxib and indomethacin. The toxic effects of these drugs on CAFs were measured using the WST method. Treatment of CAFs with serial drug concentrations revealed no significant toxicity of celecoxib and indomethacin treatment on CAFs (IC50, indomethacin: 662 µM, celecoxib: 60.09 µM; Figure 6A). Indomethacin partially restored the proliferation of CD4+ and CD8+ T cells, which was inhibited by co-culture with CAFs (Figure 6B). Treatment with different doses of celecoxib increased the proliferation of CD3+ T cells which were reduced by CAFs (Figure 6C). We also investigated whether direct cell-to-
cell contact plays an important role in these effects. T cell proliferation was reduced to a lesser extent by CAFs in the indirect co-culture condition (95.70% at PBMC+OKT3 vs 78.58% at PBMC+OKT3+CAF: net reduction of 17.12%) than in the direct co-culture condition (96.06% at PBMC+OKT3 vs 41.70% at PBMC+OKT3+CAF: net reduction of 54.36%) (Figure 6C). Therefore, the direct cell-to-cell contact is important for the full inhibitory effect of CAFs on CD3+ T cells. CD3+ T cell proliferation was partially restored by celecoxib (Figure 6C). Celecoxib also partially restored the proportion of CD8+ T cells, which was reduced by co-culture with CAFs (Figure 6D). These results revealed that CAFs inhibited the increase in OKT3-stimulated CD8+ T cell subset, but celecoxib treatment at 10 and 25 µM increased the proportion of CD8+ T cells, which was decreased by co-culture with CAFs.

**Effects of COX2 Inhibition on PD-L1 Expression in CAFs After Co-culture with Activated T Cells**

We evaluated the PD-L1 expression in CAFs after COX2 inhibition to investigate whether PD-L1 expression is regulated by COX2 activity. CAFs and activated PBMCs were treated with the selective COX2 inhibitor celecoxib (5 and 10 µM) and the PD-L1 expression was analyzed. The end-point RT-PCR and Western blot analysis demonstrated that celecoxib treatment significantly downregulated the total RNA and protein levels of PD-L1 compared to the untreated conditions (Figure 7A and B). Additionally, the expression of mPGES1 (PTGES) and secretion of PGE2, which are important downstream effectors of the COX2 pathway, were reduced by celecoxib treatment (Figure 7A and C).

**DISCUSSION**
Our results demonstrated that the expression of immune suppressive markers, such as PD-L1 and COX2, was increased in NSCLC-derived CAFs after direct co-culture with activated T cells. CAFs promote the expression of PD-L in CD4+ and CD8+ T cells, and strongly inhibit T cell proliferation. CAF-CM decreased the cytotoxicity of T cells. COX2 inhibitors restored the proliferative capacity of CD4+ and CD8+ T cells and suppressed the levels of COX2, PTGES, PGE2, and PD-L1 in CAFs.

The TME has been demonstrated as one of the regulating factors of tumor invasion and progression. CAFs are activated fibroblasts that are located within the TME, have potent tumor-modulating effects, and promote cancer recurrence and chemotherapy resistance25,26. Previous studies of NSCLC patients have found that the gene expression and methylation profiles of CAFs predicted tumor recurrence and patient survival27,28. Moreover, in patients with lung adenocarcinoma, podoplanin-positive CAFs were significantly associated with lymph node metastasis and recurrence29.

Among various cells present in the TME, CAFs play a critical role in the complex process of tumor-stroma interaction. Previous studies have reported that CAFs inhibit the T cell function by promoting the binding of the ligands PD-L1 and PD-L2 expressed on CAFs and their receptor PD-1 expressed on T cells24,30,31. Khalili et al reported that melanoma-derived fibroblast exhibited upregulation of PD-L1 and PD-L2, which were bound to PD-1 and interrupted the CD8+ T cell function30. Ghorch et al also reported that pancreatic cancer-derived CAFs expressed high levels of PD-L1 and PD-L2, and promoted the expression of immunosuppressive molecules, such as LAG-3, TIM-3, CTLA-4, and PD-1, in proliferating T cells, thereby contributing to T cell dysfunction31. In our study, OKT3 was used for T cell activation and we demonstrated that NSCLC-derived CAFs reduced the proliferation of OKT3-stimulated T cells. However, our
investigation of NSCLC patients revealed that among the co-inhibitory immune checkpoint receptors expressed on T cells, only PD1 was upregulated by the co-culture with CAFs. However, TIM-3, CTLA4, and LAG3 were not upregulated by co-culture with CAFs.

CAFs could secrete various cytokines, chemokines, and growth factors, which could contribute to chemotherapy resistance or cancer progression and metastasis\(^6\). In this study, we showed that CAF-CM could reduce the cytotoxicity of T cells in the co-culture model of autologous pair of PDOs and PBMCs (Figure 5). Although it seems that humoral factors such as cytokines or chemokines derived from CAFs influence on the cytotoxicity of T cells, further studies are needed to elucidate the exact mechanism of the alteration of T cell cytotoxicity.

Recent studies have reported that CAFs function as antigen-presenting cells. CAFs express MHC class II molecules on the cell membrane and maintain the ability to present ovalbumin peptides to CD4\(^+\) T cells \textit{in vitro}. MHC class II molecules present on CAFs act as a decoy receptor, and CAFs inactivate CD4\(^+\) T cells through differentiation into immunosuppressive Tregs or anergy induction\(^32\). In the present study, we found that the expressions of HLA-DR and two major co-stimulatory receptors (CD40 and CD80) were significantly upregulated in NSCLC-derived CAFs after coculture with PBMCs. Further studies are needed to identify the mechanisms for the expression of immunological markers in NSCLC-derived CAFs and their interactions with T cells.

Several studies have reported that COX2 is constitutively overexpressed in various cancer types, such as esophageal, head and neck, pancreatic, colon, breast, and lung; COX2 overexpression in tumors is also generally related to poor outcomes\(^{16,33,34}\). Edelman \textit{et al} reported that COX2 expression was a negative prognostic factor in
patients with advanced NSCLC\textsuperscript{35}.

Interestingly, patients with moderate to high levels of COX2 expression who received celecoxib treatment exhibited better overall survival than COX-2-expressing patients who did not receive celecoxib\textsuperscript{35}. Our co-culture experiments revealed that CAFs induced PD-1 expression in activated T cells through a direct cell-to-cell contact mechanism and a COX2-dependent manner. We also found that COX2 inhibitors significantly reduced the PD-L1 expression in CAFs. In the present study, COX2 signaling played an important role in the immunosuppressive function of NSCLC-derived CAFs by regulating PD-L1 expression. More research is needed to evaluate the combination of COX2 inhibitors and immune checkpoint inhibitors in NSCLC patients.

In conclusion, CAFs promote immune evasion by suppressing the function of CD4\textsuperscript{+} and CD8\textsuperscript{+} T cells via their effects on COX2 and PD-L1. Furthermore, the immunosuppressive function of CAFs was alleviated by COX2 inhibitors.
References


Figure 1. Characterization of human lung CAFs and NFs. (A) Cell morphology of cultured CAFs and NFs (TH127) was visualized under a microscope. Scale bar, 200 µm. (B) Immunocytochemistry revealed that only CAFs (TH122) expressed αSMA, which is a marker of CAFs (red: αSMA, blue: DAPI). Scale bar, 20 µm. (C) Real-time PCR for mRNA expression levels of fibroblast-associated genes in paired NFs and CAFs from two patients (TH122 and TH131). Expression levels were normalized to GAPDH mRNA. Significance was assessed using an unpaired t-test. *p < 0.05, **p < 0.01, ***p < 0.001, ns = not significant.
Figure 2. Expression of immunological markers and immunosuppressive molecules (COX2 and PD-L1) in CAFs after co-culture with PBMCs. (A) Comparison of HLA-DRB, co-stimulatory receptors (CD40 and CD80), and immune suppressive molecules (PD-L1, PD-L2, and COX2) in CAFs with or without PBMCs in unstimulated and stimulated conditions. One-way ANOVA and Tukey’s multiple comparison tests were used to determine the significance of comparisons (*p < 0.05, **p < 0.01, ***p < 0.001). (B–D) Expression of PD-L1 and COX2 in CAFs with and without PBMCs from healthy donors under unstimulated and stimulated conditions. (B)
End-point PCR, (C) Western blot, and (D) immunocytochemistry for CAFs (TH100) alone and CAFs with activated PBMCs (green: COX2 and PD-L1; blue: DAPI).
Figure 3. CAFs suppress CD4+ and CD8+ T cell proliferation. OKT3-stimulated PBMCs were co-cultured with and without CAFs. (A) Representative CFSE histograms for CD4+ and CD8+ T cells from healthy donors. (B) Proliferation of CD4+ and CD8+
T-cells from healthy donors with and without allogeneic CAFs (TH100, 106, and 107; n = 3). (C) Representative CFSE histograms. (D) Proliferation of patient-derived CD4+ and CD8+ T cells with and without autologous CAFs (TH91, 96, 98, and 114; n = 4). (E) CAFs inhibit an increase in CD8+ T cell subtypes among stimulated CD3+ T cells (TH100). (F) Proportions of CD4+ and CD8+ T-cells with and without allogeneic CAFs (TH100, 106, and 107; n = 3) in OKT3 unstimulated and stimulated conditions. The significance of difference was compared using the unpaired t-test (*p < 0.05, **p < 0.01, ***p < 0.001).
Figure 4. CAFs promote the expression of PD-1 on cytotoxic T and helper T cells.
(A) Representative flow cytometry contour plot (TH100) and (B) proportions of PD-1 expression with and without allogeneic CAFs (TH100, 106, and 107; n = 3) in OKT3 stimulated and unstimulated conditions. The significance of difference was evaluated using the unpaired t-test (***p < 0.001). (C and D) Representative flow cytometry contour plot showing the expressions of CTLA4, LAG3, and TIM3 on (C) CD8+ and (D) CD4+ T cells with and without allogeneic CAFs (TH100) in OKT3 stimulated conditions.
Figure 5. CAF-CM reduced T cell cytotoxicity in the tumor organoid killing assay.

Tumor organoid killing assay was performed using the autologous pair of PDOs and PMBCs (TH189). CAF-CM was harvested using CAFs derived from the same patient (TH189). The mixture of PDOs & PBMCs (1:2 ratio) were co-cultured in organoid culture medium containing ICPIs in the presence or absence of 50% CAF-CM for 7 days. (A) 3D cell viability assay showing that tumor organoid killing by T-cell were reduced by the treatment of CAF-CM in pembrolizumab (P), nivolumab (N), and atezolizumab (A) groups, respectively (all p < 0.05). (B) Representative light microscopy images showing that the sizes of organoids were smaller in the groups without CAF-CM than in those with CAF-CM.
Figure 6. COX-2 inhibitors restored T cell proliferation and the proportion of CD8+ T cells. (A) CAFs (TH100) were treated with various concentrations of indomethacin and celecoxib for 72 h, and cell viability was measured using the WST assay. (B) CFSE histograms for CD4+ and CD8+ T-cells. PBMCs and CAFs (TH100) were co-cultured with and without 40 µM indomethacin and stimulated with OKT3. (C)
CFSE histograms for CD3+ T-cells. PBMCs and CAFs (TH100) were co-cultured in 10 and 25 µM celecoxib and 15 ng/mL OKT3 for 5 days under direct and indirect conditions. (D) PBMCs were activated with OKT3 (15 ng/mL) and treated with celecoxib (10 and 25 µM) in the presence of CAFs (TH100).
Figure 7. Downregulation of COX2, PTGES, and PD-L1 in CAFs treated with celecoxib. CAFs (TH100) were co-cultured with activated PBMCs and incubated with or without celecoxib (5 and 10 µM). (A) After 5 days of incubation, mRNA expressions of COX2, PTGES (prostaglandin E synthase), and PD-L1 in CAFs were analyzed by real-time PCR analysis. One-way ANOVA and Tukey’s multiple comparison test were used to determine the significance of differences (***p < 0.001). (B) After 5 days of incubation, CAFs were harvested and the protein expressions were analyzed by Western blot. (C) After 5 days of incubation, PGE2 secretion were measured by ELISA.
<table>
<thead>
<tr>
<th>CAF/NF</th>
<th>Sex</th>
<th>Age</th>
<th>Smoking history</th>
<th>Tissue of origin</th>
<th>Histological subtype</th>
<th>Stage</th>
<th>Genotype of lung cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td>TH91-CAF</td>
<td>M</td>
<td>68</td>
<td>Smoker</td>
<td>Lymph Node</td>
<td>NSCLC NOS</td>
<td>IIIC</td>
<td>NA</td>
</tr>
<tr>
<td>TH96-CAF</td>
<td>M</td>
<td>72</td>
<td>Smoker</td>
<td>Lymph Node</td>
<td>ADC IVA</td>
<td></td>
<td>EGFR exon 19 del</td>
</tr>
<tr>
<td>TH98-CAF</td>
<td>F</td>
<td>60</td>
<td>Never smoker</td>
<td>Lung ADC</td>
<td>IIIA</td>
<td></td>
<td>EGFR exon 19 del</td>
</tr>
<tr>
<td>TH100-CAF</td>
<td>F</td>
<td>57</td>
<td>Smoker</td>
<td>Lung ADC</td>
<td>IIB</td>
<td></td>
<td>EGFR exon 19 del &amp; T790M</td>
</tr>
<tr>
<td>TH106-CAF</td>
<td>M</td>
<td>69</td>
<td>Smoker</td>
<td>Lymph Node</td>
<td>SqCC IIIB</td>
<td></td>
<td>NA</td>
</tr>
<tr>
<td>TH107-CAF</td>
<td>F</td>
<td>58</td>
<td>Never smoker</td>
<td>Lung ADC</td>
<td>IB ALK rearrangement</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TH114-CAF</td>
<td>M</td>
<td>70</td>
<td>Smoker</td>
<td>Lung SqCC</td>
<td>IB NA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TH122-CAF/NF</td>
<td>M</td>
<td>54</td>
<td>Smoker</td>
<td>Lung SqCC</td>
<td>IIIA NA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TH127-CAF/NF</td>
<td>M</td>
<td>68</td>
<td>Smoker</td>
<td>Lung ADC</td>
<td>IB NA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TH131-CAF/NF</td>
<td>M</td>
<td>60</td>
<td>Smoker</td>
<td>Lung SqCC</td>
<td>IIB NA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TH189-CAF</td>
<td>M</td>
<td>65</td>
<td>Smoker</td>
<td>Lung SqCC</td>
<td>IIB MSH6 T1355fs</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

CAF, cancer-associated fibroblast; NF, normal fibroblast; EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase; ADC, adenocarcinoma; SqCC, squamous cell carcinoma.
squamous cell carcinoma; NSCLC NOS, non-small cell lung cancer, not otherwise specified; NA, not available.
## Supplementary Table S1. Antibodies used in this study

<table>
<thead>
<tr>
<th>Markers</th>
<th>Fluorochrome</th>
<th>Clone</th>
<th>Company</th>
<th>Catalogue number</th>
<th>Application</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD3</td>
<td>PerCP</td>
<td>UCHT1</td>
<td>Biolegend</td>
<td>300428</td>
<td>Flow cytometry</td>
</tr>
<tr>
<td>CD4</td>
<td>PE</td>
<td>RPA-T4</td>
<td>Biolegend</td>
<td>300508</td>
<td>Flow cytometry</td>
</tr>
<tr>
<td>CD8</td>
<td>APC-Cy™7</td>
<td>SK1</td>
<td>BD</td>
<td>557834</td>
<td>Flow cytometry</td>
</tr>
<tr>
<td>CD279</td>
<td>BV421</td>
<td>EH12.1</td>
<td>BD</td>
<td>562516</td>
<td>Flow cytometry</td>
</tr>
<tr>
<td>CD366</td>
<td>BV421</td>
<td>7D3</td>
<td>BD</td>
<td>565562</td>
<td>Flow cytometry</td>
</tr>
<tr>
<td>CD152</td>
<td>BV421</td>
<td>BNI13</td>
<td>BD</td>
<td>562743</td>
<td>Flow cytometry</td>
</tr>
<tr>
<td>CD223</td>
<td>BV421</td>
<td>11C3C65</td>
<td>Biolegend</td>
<td>369314</td>
<td>Flow cytometry</td>
</tr>
<tr>
<td>α-SMA</td>
<td>No</td>
<td>1A4</td>
<td>Abcam</td>
<td>ab7817</td>
<td>ICC, WB</td>
</tr>
<tr>
<td>PD-L1</td>
<td>No</td>
<td>E1L3N</td>
<td>Cell Signaling</td>
<td>13684</td>
<td>ICC, WB</td>
</tr>
<tr>
<td>Cox2</td>
<td>No</td>
<td>D5H5</td>
<td>Cell Signaling</td>
<td>12282</td>
<td>ICC, WB</td>
</tr>
<tr>
<td>β-Actin</td>
<td>No</td>
<td>C4</td>
<td>Santa Cruz</td>
<td>sc-47778</td>
<td>WB</td>
</tr>
<tr>
<td>Antibody</td>
<td>Clone</td>
<td>Catalog Number</td>
<td>Supplier</td>
<td>Dilution</td>
<td>Method</td>
</tr>
<tr>
<td>----------</td>
<td>-------</td>
<td>----------------</td>
<td>----------</td>
<td>----------</td>
<td>--------</td>
</tr>
<tr>
<td>GAPDH mouse anti-rabbit</td>
<td>No</td>
<td>FL-335</td>
<td>Santa Cruz sc-25778</td>
<td>WB</td>
<td></td>
</tr>
<tr>
<td>IgG-HRP</td>
<td>No</td>
<td>Santa Cruz sc-2357</td>
<td>WB</td>
<td></td>
<td></td>
</tr>
<tr>
<td>m-IgGk BP-HRP</td>
<td>No</td>
<td>Santa Cruz sc-516102</td>
<td>WB</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Goat anti-Alexa Fluor Rabbit</td>
<td>488</td>
<td>Invitrogen A-11034</td>
<td>ICC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Goat IgG</td>
<td>488</td>
<td>Invitrogen A-11029</td>
<td>ICC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Goat anti-Alexa Fluor Mouse IgG</td>
<td>488</td>
<td>Invitrogen A-11036</td>
<td>ICC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Goat anti-Alexa Fluor Rabbit IgG</td>
<td>568</td>
<td>Invitrogen A-11036</td>
<td>ICC</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**Supplementary Table S2. Primer sequences used for real time PCR**

<table>
<thead>
<tr>
<th>Gene</th>
<th>Reference sequence number</th>
<th>Primer sequences</th>
<th>Product size (bp)</th>
<th>Tm (°C)</th>
</tr>
</thead>
<tbody>
<tr>
<td>FAP</td>
<td>NM_00446.0.5</td>
<td>F-CCAGAATGTTCTGCTG</td>
<td>154</td>
<td>57.81/ 55.99</td>
</tr>
<tr>
<td></td>
<td></td>
<td>R-CGAAATGGCATCAGCTGA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ACTA2</td>
<td>NM_00114.1945.2</td>
<td>F-GCTGTTCCTTCACCATGTTT</td>
<td>148</td>
<td>56.57/ 57.19</td>
</tr>
<tr>
<td></td>
<td></td>
<td>R-TGGTGATGATGCCCAGTCT</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PDPN</td>
<td>AF390106.1</td>
<td>F-CTGCTCTTTTTGGGAAG</td>
<td>190</td>
<td>57.02/ 58.32</td>
</tr>
<tr>
<td></td>
<td></td>
<td>R-TTGCCACCAGAGTTGCAAG</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ITGA11</td>
<td>NM_00100.4439.2</td>
<td>F-AAAGTGCCAGACCTACATGG</td>
<td>154</td>
<td>59.38/ 58.56</td>
</tr>
<tr>
<td></td>
<td></td>
<td>R-TTCCACATAGCTGACA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TNC</td>
<td>NM_00216.0.4</td>
<td>F-CCACAAATGGCAGATCCTGT</td>
<td>157</td>
<td>57.57/ 60.25</td>
</tr>
<tr>
<td></td>
<td></td>
<td>R-GTFAACGCCCCTGACTGTG</td>
<td></td>
<td></td>
</tr>
<tr>
<td>FSP1</td>
<td>NM_00296.1.3</td>
<td>F-GGTTGCCACCTCCACAAGT</td>
<td>161</td>
<td>59.82/ 58.98</td>
</tr>
<tr>
<td></td>
<td></td>
<td>R-TGTTTGCTGCCAGTTTGCT</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PDGFRA</td>
<td>NM_00620.6.6</td>
<td>F-GGCCCATTTACATCATCAC</td>
<td>160</td>
<td>56.53/ 58.27</td>
</tr>
<tr>
<td></td>
<td></td>
<td>R-CATAGCTGGTGCTTTTC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PDGFRB</td>
<td>NM_00260.9.4</td>
<td>F-TCACTGCCAGCTGACTTCC</td>
<td>148</td>
<td>59.68/ 60.11</td>
</tr>
<tr>
<td></td>
<td></td>
<td>R-CAGGGTGGCTCTCATTAGC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PDL1</td>
<td>AY254342.1</td>
<td>F-TATGGTGCTGGCGACTACAA</td>
<td>157</td>
<td>58.73/ 57.92</td>
</tr>
<tr>
<td></td>
<td></td>
<td>R-TGCTTGCCAGTGACTTCG</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PDL2</td>
<td>NM_02523.9.4</td>
<td>F-TCAGAATGTTCTCAGTGC</td>
<td>184</td>
<td>57.34/ 56.56</td>
</tr>
<tr>
<td></td>
<td></td>
<td>R-GGCGGACCACATAGATGATT</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gene</td>
<td>Accession</td>
<td>Log2Ct Value</td>
<td>F-Primers</td>
<td>R-Primers</td>
</tr>
<tr>
<td>----------</td>
<td>-----------</td>
<td>--------------</td>
<td>-----------------------</td>
<td>-----------------------</td>
</tr>
<tr>
<td>HLA-DR B</td>
<td>X12544.1</td>
<td>157</td>
<td>F-ACAACTACGGGGTTGGAG</td>
<td>R-CGGAACCACCTGACTTCAAT</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CD40</td>
<td>NM_00125</td>
<td>0.6</td>
<td>F-GCCAAGAAGCCAACCAATAA</td>
<td>R-ATGCCGACTCTCTTTGCCATC</td>
</tr>
<tr>
<td></td>
<td>1.4</td>
<td>158</td>
<td>F-CTCGCATCTACTGGAAAAAG</td>
<td>R-GTATGTGCCCCTCGTCAGATG</td>
</tr>
<tr>
<td>CD80</td>
<td>NM_00204</td>
<td>6.5</td>
<td>F-CATCATCCCTGCTCTACTG</td>
<td>R-TTGGCAGGTTTTCTAGACG</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GAPDH</td>
<td>NM_00204</td>
<td>147</td>
<td>F-CATCATCCCTGCTCTACTG</td>
<td>R-TTGGCAGGTTTTCTAGACG</td>
</tr>
</tbody>
</table>